Compare FLYX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLYX | KRRO |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 101.1M |
| IPO Year | N/A | N/A |
| Metric | FLYX | KRRO |
|---|---|---|
| Price | $2.36 | $11.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $54.60 |
| AVG Volume (30 Days) | 203.4K | ★ 294.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.72 | $145.97 |
| Revenue Next Year | $8.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $5.20 |
| 52 Week High | $8.88 | $55.89 |
| Indicator | FLYX | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 39.03 | 51.81 |
| Support Level | $2.56 | $10.81 |
| Resistance Level | $3.31 | $12.46 |
| Average True Range (ATR) | 0.32 | 1.11 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 4.63 | 16.69 |
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.